N-(2,2-Dimethyl-propyl)-guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2,2-Dimethyl-propyl)-guanidine
• 英文别名: Neopentylguanidine；2-(2,2-dimethylpropyl)guanidine
• 化学式: C₆H₁₅N₃
• 分子量: 129.205
• InChiKey: UQIFFFDQJBCHGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(2,2-Dimethyl-propyl)-guanidine 在 potassium carbonate 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

  摘要：

  The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC(50)s <= 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

  DOI：

  10.1021/ml500240d
• 作为产物：
  描述：

  S-甲基异硫脲硫酸盐 、 特戊胺 以 水 为溶剂， 生成 N-(2,2-Dimethyl-propyl)-guanidine
  参考文献：
  名称：

  交感神经系统阻滞剂。V.异丁基-，叔丁基-和新戊基胍的衍生物。

  摘要：

  DOI：

  10.1021/jm00312a006

文献信息

• BETA-LACTAMASE INHIBITORS
  申请人：Cubist Pharmaceuticals, Inc.

  公开号：US20130296555A1

  公开（公告）日：2013-11-07

  Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains.

  本披露揭示了取代芳基的二氮杂双环辛烷（DBO）化合物，其抑制A类、C类或D类β-内酰胺酶并增强β-内酰胺类抗生素的作用。具体而言，本披露提供了DBO化合物，当与β-内酰胺抗生素在固定浓度下在披露的Synergy MIC测定中使用时，对一个或多个同源β-内酰胺酶表达细菌菌株的最低抑菌浓度（MIC）为8 μg/mL或更低。
• Antibiotic compounds
  申请人：Liu Kun

  公开号：US20080132500A1

  公开（公告）日：2008-06-05

  Certain water-soluble thiazolyl peptides are antibiotic capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be employed as versatile intermediates for the preparation of new derivatives with useful antibacterial activity.

  某些水溶性噻唑肽是抗生素，能够治疗哺乳动物，尤其是人类的严重细菌感染。其中一些类似物也可以作为多功能中间体，用于制备具有有用抗菌活性的新衍生物。
• ADAM10 and its Uses Related to Infection
  申请人：Rubin Donald H.

  公开号：US20090220514A1

  公开（公告）日：2009-09-03

  The present invention relates to a protein, ADAM10, ADAM10 nucleic acid sequences and ADAM10 proteins encoded by these sequences that are involved in infection by one or more pathogen such as a virus, a parasite, a bacteria or a fungus or are otherwise associated with the life cycle of a pathogen.

  本发明涉及一种蛋白质ADAM10，ADAM10核酸序列和由这些序列编码的ADAM10蛋白质，它们参与感染一种或多种病原体，例如病毒、寄生虫、细菌或真菌，或与病原体的生命周期有关。
• INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20090240027A1

  公开（公告）日：2009-09-24

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，其为胃动素受体拮抗剂，并可用于治疗与该受体及运动功能障碍相关的疾病。
• INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：Roth Juergen Gerald

  公开号：US20070004757A1

  公开（公告）日：2007-01-04

  The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R 1 to R 6 and X are as defined in Claim 1 , to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.

  本发明涉及6-位取代的吲哚酮衍生物，其化学式为其中R1至R6和X如权利要求1所定义，以及它们的互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其生理上可接受的盐，具有有用的药理学性质，特别是在抑制各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖方面，以及包含这些化合物的药物、它们的用途和制备方法。